LUCAS WONG to Treatment Outcome
This is a "connection" page, showing publications LUCAS WONG has written about Treatment Outcome.
Connection Strength
0.087
-
High- versus low-dose leucovorin in the modified FOLFOX6 regimen for first-line treatment of metastatic colorectal cancer. J Oncol Pharm Pract. 2017 Apr; 23(3):173-178.
Score: 0.045
-
A randomized trial of nurse-administered behavioral interventions to manage anticipatory nausea and vomiting in chemotherapy. Cancer Med. 2020 03; 9(5):1733-1740.
Score: 0.014
-
Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC. Lung Cancer. 2017 09; 111:108-115.
Score: 0.012
-
A phase II, randomized, double blind trial of calcium aluminosilicate clay versus placebo for the prevention of diarrhea in patients with metastatic colorectal cancer treated with irinotecan. Support Care Cancer. 2015 Mar; 23(3):661-70.
Score: 0.010
-
Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336). Invest New Drugs. 2009 Oct; 27(5):469-75.
Score: 0.007